A 2-month-old infant with Enterobacter osteomyelitis complicating total parenteral nutrition was successfully treated with rifampicin and chloramphenicol. No untoward side effects attributed to rifampicin has been noted despite prolonged administration of rifampicin.
Introduction
One of the most serious complications of total parenteral nutrition (TPN) is suppurative phlebitis and consequent septicaemia. Candida spp., coagulase-positive Staphylococcus aureus and, in recent years, multiple resistant Gram-negative bacilli (especially Klebsiella and Enterobacter) have been implicated most frequently (Heird et al., 1972; Lloyd-Still, Shwachman and Filler, 1973; Maki, Goldman and Rhame, 1973) . Rifampicin, rarely used in non-tuberculous infections, has proved to be useful in combination with chloramphenicol in curing an infant with resistant Enterobacter osteomyelitis complicating TPN. Because of the widespread use of intravenous alimentation in medical and surgical departments and the potential risk of complications, it was felt that the sharing with other paediatricians of this successful experience would be of value.
Case report
A 2-month-old male infant was admitted with diarrhoea from birth. He was born after normal pregnancy and delivery. Birth weight was 2900 g. (Dich, Nelson and Haltalin, 1975 Rifampicin, an orally active bactericidal antibiotic, proved to be effective in resistant Gramnegative infections due to Klebsiella, E. coli and Shigella Friedman, 1973, 1974 Strahovsky and Friedman, 1977) . Untoward side effects have not been observed in any of the patients, not even in an 8-month-old infant after prolonged administration of rimfampicin for Klebsiella osteomyelitis (Naveh and Friedman, 1973) . So far as the authors know, complications following rifampicin therapy have rarely, if ever, been reported in the paediatric age group. This might be owing to the limited experience with the drug in children and/or to the relatively shorter courses given to infants suffering from non-tuberculous infections. Mild hepatic injury, mostly reversible, has been reported in adults suffering from tuberculosis and getting combined therapy of rifampicin and isoniazid which also is an hepatotoxic agent (Klatskin, 1975; Mattson, 1973; Scheuer et al., 1974) . It is difficult to ascribe a hepatotoxic reaction to any one antituberculous agent because patients usually receive several drugs together (Scheuer et al., 1974) . Rifampicin hepatitis is characterized by early onset (Graisely et al., 1971; Scheuer et al., 1974) and the earlier the onset of the hepatitis the more severe it tends to be (Scheuer et al., 1974) . The jaundice appeared in the present patient 2 days after discontinuation of a 2-month course of rifampicin therapy. This late onset and the fulminant course are not characteristic of rifampicin hepatitis. In the absence of evidence of bacterial infection, increased IgM supports recent viral infection. The positivity of serum to Australia antigen makes hepatitis B virus the most probable causative organism. Luboshitzky, Sacks and Michel (1973) found that the effect of rifampicin in combination with other antibiotics was no different from that when rifampicin was given alone. The present authors also felt that the combination of chloramphenicol and rifampicin was unnecessary and therefore chloramphenicol was discontinued after 3 weeks without any deterioration of the patient's general condition. They are convinced that similar improvement could be achieved without any combination.
In view of the paucity of papers on the use of rifampicin in non-tuberculous infections in child- 
